Amerant Bancorp vs California BanCorp CA
AMTB and BCAL side by side, both in commercial banks. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMTB and BCAL compare
Amerant Bancorp is the larger company, worth 1.7 times as much as California BanCorp CA ($1.2B against $702M).
On earnings, California BanCorp CA is cheaper: it trades at 11.9× trailing earnings, against 21.8× for Amerant Bancorp.
Amerant Bancorp grew revenue faster over the last twelve months (17.1% versus 4.3% for California BanCorp CA).
California BanCorp CA keeps more of each dollar of sales as profit, with a net margin of 33.4% compared with 13.4% at Amerant Bancorp.
Both pay dividends: Amerant Bancorp yields 0.89% and California BanCorp CA 1.9%.
California BanCorp CA scores higher on the StockData Score (13 against 9 for Amerant Bancorp), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMTB | BCAL |
|---|---|---|
| Size and price | ||
| Market cap | $1.2B | $702M |
| Share price | $30.27 | $21.85 |
| Change, 1 year | 70.2% | 15.2% |
| Change, 5 years | 3.5% | 41.9% |
| Beta (5Y) | 0.20 | 0.16 |
| Employees | 694 | 288 |
| StockData Score | ||
| Total score | 9 | 13 (better) |
| Valuation score | 1 | 2 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 0 | 3 (better) |
| Health score | 4 | 5 (better) |
| Dividend score | 3 (better) | 1 |
| Valuation | ||
| P/E | 21.8× | 11.9× (better) |
| P/S | 2.8× (better) | 3.9× |
| P/B | 1.3× | 1.2× (better) |
| P/FCF | 11.4× (better) | 11.9× |
| PEG | – | 0.40 |
| FCF yield | 8.8% (better) | 8.4% |
| Fair value | $21.60 | $21.70 |
| Margin of safety | −40.1% | −0.69% (better) |
| Growth | ||
| Revenue growth (TTM) | 17.1% (better) | 4.3% |
| Revenue growth, 5Y average | 10.8% | – |
| Net income growth (TTM) | 1433% (better) | 92.6% |
| EPS growth (TTM) | – | 114% |
| Profitability | ||
| Net margin | 13.4% | 33.4% (better) |
| FCF margin | 24.8% | 32.9% (better) |
| Return on equity | 6.1% | 10.6% (better) |
| Financial health | ||
| Altman Z-score | 0.21 | 0.22 (better) |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | 0.89% | 1.9% (better) |
| Payout ratio | 26.2% | – |
| Buyback yield | 4.9% (better) | 1.8% |
| Shareholder yield | 5.8% (better) | 3.7% |
| Ownership | ||
| Held by institutions | 74.5% | 71.0% |
| Held by insiders | 3.2% | 8.6% |
| Insider net buying, 12 months | $143K (better) | −$46.0M |
| Short interest, % of float | 4.8% | 3.1% |
Go deeper
- AMTB stock overview
- AMTB income statement
- AMTB valuation and score
- BCAL stock overview
- BCAL income statement
- BCAL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.